Logo
LUMIFIL L Lite with Lidocaine 1 x 1ml

LUMIFIL L Lite with Lidocaine 1 x 1ml

LUMIFIL

Dermal filler
  • Class III CE Marked medical device within the EU/EEA for use as an injectable hyaluronic acid dermal filler.
  • Manufactured by BNC Korea under an established quality management system consistent with ISO 13485 and relevant medical device regulations (as stated by distributors).
  • Marketed for professional use only, with many distributors restricting supply to medical or appropriately trained aesthetic practitioners in line with local regulations.
  • Product labelling and IFU include CE mark, batch/lot identification, expiry date, storage conditions and device classification to support regulatory compliance.
Low-viscosity ultra-fine hyaluronic acid filler for fine lines and subtle lip augmentation

Description

LUMIFIL L-Lite with Lidocaine is a low-viscosity, ultra-fine hyaluronic acid dermal filler designed for fine lines and low-volume enhancements. Developed using non-animal derived, high molecular weight hyaluronic acid (approximately 2,500,000 Da) and cross-linking technology, it is formulated to provide precise, site-specific contouring with minimal product migration. L-Lite is indicated for crow’s feet, perioral (smoker’s) lines, light forehead lines, and lip contouring/augmentation, and is particularly favoured for Russian Lip techniques where refined detail and a natural lift are desired. The patented Particle Plastic (PP) process produces uniform HA particle structure with optimised viscoelasticity, enabling smooth injectability, natural-looking results and durable volume. The addition of 0.3% lidocaine improves treatment comfort for patients during injection, while results are typically marketed to last around 12–15 months, depending on lifestyle and individual factors.

Bnefits

  • Ultra-fine texture for highly precise, site-specific contouring and detailing in delicate areas.
  • Low-viscosity formula that spreads smoothly while still delivering controlled lift and subtle volume.
  • Low product migration, helping the filler remain localised near the injection site for predictable results.
  • Natural-looking aesthetic outcome with superior control, ideal for subtle lip and perioral enhancement.
  • High viscoelasticity that offers long-lasting volume and shape retention.
  • High molecular weight HA (approx. 2,500,000 Da), providing one of the densest HA structures in this segment for extended effect.
  • Patented Particle Plastic (PP) process ensuring uniform HA particle structure and optimised rheology.
  • Smooth injectability characteristics, supporting easier injections and moulding with less resistance.
  • Contains 0.3% lidocaine to reduce pain and discomfort during treatment, enhancing patient experience.
  • Favoured for detailed lip techniques including Russian Lip, where controlled, natural lift is required.

Indications

  • Crow’s feet and fine periocular lines.
  • Perioral (smoker’s) lines around the mouth.
  • Light forehead lines and mild facial wrinkles.
  • Lip contouring and subtle lip augmentation (including Russian Lip technique).
  • Fine to medium lines in delicate facial regions such as under-eye, glabellar and marionette lines, based on distributor indications.
  • Low-volume enhancement where refinement rather than strong bulk is desired.

Composition

  • Active ingredient: Cross-linked hyaluronic acid (HA) 20 mg/ml.
  • Local anaesthetic: Lidocaine 0.3% (3 mg/ml) to reduce injection discomfort.
  • Hyaluronic acid is non-animal derived and of high molecular weight (approximately 2,500,000 Da) before cross-linking.
  • Sterile, pyrogen-free monophasic HA gel in phosphate-buffered saline and excipients as listed in the official IFU.

Formulation

  • Monophasic, low-viscosity, ultra-fine cross-linked hyaluronic acid dermal filler.
  • High molecular weight HA (2,500,000 Da) processed using a patented Particle Plastic (PP) process for uniform particle structure.
  • High viscoelasticity and low phase angle, designed to maintain filler at the injection site for longer.
  • Includes 0.3% lidocaine to enhance patient comfort during injection.
  • Formulated specifically for superficial to mid-dermal injection in areas of fine lines and subtle volume loss.

Packaging

  • Each unit pack contains 1 x 1 ml pre-filled sterile syringe of LUMIFIL L-Lite with Lidocaine.
  • Many distributors specify that two sterile needles (typically 30G) are included per box, though exact needle specification should be confirmed on the package.
  • Packaging is CE-marked and labelled with batch number, expiry date, storage conditions and instructions for use.
  • Supplied as a single-patient, single-use medical device for professional administration.

Usage

  • For professional use only by licensed healthcare or aesthetic practitioners trained in dermal filler injection techniques.
  • Indicated injection depth is generally the superficial to mid-dermis, depending on the area and severity of lines.
  • Typical treatment areas include crow’s feet, perioral lines, light forehead lines, lip border and body (for contouring and subtle augmentation), and other fine-line areas as indicated.
  • Use aseptic technique: clean and disinfect the skin, wear sterile gloves, and use sterile needles and equipment.
  • Common injection techniques include serial puncture, linear threading and micro-bolus injections adapted to the anatomical site and desired effect.
  • Inject slowly with minimal pressure; aspirate according to clinic protocol where appropriate, taking care to avoid intravascular injection.
  • After injection, gently mould and contour the filler if needed to achieve a smooth, even result while avoiding excessive manipulation.
  • Provide patients with written post-treatment advice, such as avoiding makeup, intense exercise, alcohol, and extreme temperatures (saunas, sunbeds) for 24 hours or per clinic policy.
  • Advise patients to monitor for early signs of complications (e.g. unusual pain, blanching, colour change, visual symptoms) and to seek immediate review if they occur.
  • Always consult and follow the official Instructions for Use (IFU) and local clinical guidelines for detailed protocols, contraindications and management of complications.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or any other component of the product.
  • Presence of active skin infection, inflammation or disease at or near the intended injection site (e.g. herpes simplex, acne flare, dermatitis).
  • History of severe anaphylactic reactions or multiple severe allergies where elective injectable treatments present increased risk.
  • Patients with autoimmune diseases, coagulation disorders, uncontrolled systemic illness or those who are immunosuppressed, unless the treating clinician determines use is appropriate following a risk–benefit assessment.
  • Pregnancy and breastfeeding, as elective aesthetic filler procedures are generally avoided in the absence of adequate safety data.
  • Previous permanent filler or foreign-body implants in the planned treatment area where interaction risk exists, unless a suitably qualified practitioner determines it is safe to proceed.
  • Any additional contraindications, cautions or patient exclusions specified in the official Instructions for Use or required by local regulations and professional guidelines.

Adverse Effects

  • Common transient injection-site reactions such as redness, swelling, tenderness, bruising, pain, itching or slight induration.
  • Potential for small lumps, nodules, asymmetry or irregularities if injection depth or placement is suboptimal or if product is over- or unevenly placed.
  • Risk of infection if aseptic technique is not strictly followed, including possible abscess or cellulitis.
  • Rare hypersensitivity or delayed inflammatory reactions to hyaluronic acid or lidocaine.
  • Serious but rare complications associated with all HA fillers, including intravascular injection leading to vascular occlusion, tissue ischaemia or necrosis, and in very rare cases visual disturbance or blindness if vessels supplying the ocular region are affected.
  • Patients should receive clear information about signs of complications (e.g. increasing pain, blanching, dusky or mottled skin, visual changes, severe swelling or signs of infection) and be instructed to seek urgent medical review if these occur.
  • Practitioners must be trained and equipped to manage complications, including the use of hyaluronidase where appropriate, and follow local adverse event reporting requirements.

Storage Conditions

  • Store LUMIFIL L-Lite in its original packaging at controlled room temperature, typically between 1°C and 30°C.
  • Protect from direct sunlight and do not freeze.
  • Keep out of reach of children and unauthorised persons; store in a secure clinical environment.
  • Do not use if the blister or syringe packaging is damaged, if the solution appears discoloured or contains particulates, or if the product is past its expiry date.
  • Follow any additional storage instructions provided on the outer carton and in the IFU, including shelf-life from date of manufacture.

Duration

Marketing and distributor information commonly state that LUMIFIL L-Lite results last approximately 12\u201315 months, depending on the patient\u2019s skin, metabolism and lifestyle. Some sources note that maintenance sessions every 3\u20136 months can help prolong effects, and actual longevity may vary between roughly 9 and 15 months based on individual factors and injection site.

Onset

As with other hyaluronic acid dermal fillers, volume enhancement and smoothing are visible immediately after injection. Final results become more apparent once initial swelling and redness subside, typically within a few days to about two weeks.

Browse more Dermal filler

Top Treatments

Top Cities in the UK